Figure 1

Effects of the Tat-Cav3.2-III-IV linker peptide in mouse models of visceral pain and diabetic neuropathy. (A) Blind analyses of writhing responses of mice treated with the Tat-3.2-III-IV linker (10.0 μg/i.t.) or the Tat-3.2-CT (control, 10.0 μg/i.t.) peptides 1 hour prior to acetic acid injections. (B) total number of writhing responses of acetic acid injected mice treated with Tat-3.2-III-IV linker or the Tat-3.2-CT peptides. (C) Time course of antihyperalgesic effect of the Tat-3.2-III-IV linker (10.0 μg/i.t.) or the Tat-3.2-CT (10.0 μg/i.t.) peptides delivered to diabetic neuropathic (ob/ob) and wild-type mice. The experimenter was blind to the treatment in panels A, B and C. Each circle/bar represents the mean ± S.E.M. (n=7 in panel C; and n=10 in panels A and B) and is representative of 2 independent sets of experiments. Statistical analyses were performed by two-way ANOVA followed by a Tukey’s test (panels A and C), and unpaired Student’s t-test (panel B). The dashed line and hashtag indicate the range of data points where diabetic neuropathic animals differed from the non-diabetic group (P<0.001).